Results 101 to 110 of about 2,835 (182)

Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis

BACKGROUND: Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment of ulcerative colitis in Scotland in May 2022. We present the first real-world experience on its use in clinical practice. METHODS:
Goodall, M, Plevris, N, O’Hare, C, Gros, B, Constantine-Cooke, N, Jones, GR, Arnott, ID, Elford, AT, Lees, CW, Noble, C   +9 more
core   +1 more source

Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators. [PDF]

Drugs Aging
Derijks LJJ, Karapinar-Çarkit F, Mujagić Z, van Marum RJ, Pierik MJ.   +4 more
europepmc   +1 more source

Filgotinib for the Treatment of Small Bowel Crohn’s Disease: The DIVERGENCE 1 Trial

Gastroenterology, 2023
D'Haens, Geert R., Lee, Scott, Taylor, Stuart A., Serone, Adrian, Rimola, Jordi, Colombel, Jean-Frederic, Besuyen, Robin, Gecse, Krisztina, McKevitt, Matt, Reinisch, Walter, Ren, Xuehan, Schwartz, David   +11 more
openaire   +2 more sources

Region-specific immune regulation determines differential response to JAK1 inhibition in Crohn's disease ex vivo. [PDF]

J Crohns Colitis
Grieger KM, Dehmel S, Schröder V, Schmidt K, Neufeldt V, Bock L, Schaudien D, Kulik U, Wagner A, Gundert B, Aselmann H, Neuhaus V, Braun A, Sewald K.   +13 more
europepmc   +1 more source

Pure red cell aplasia in a patient with rheumatoid arthritis after JAK inhibitor exposure-diagnostic challenges. [PDF]

Oxf Med Case Reports
Rajnarinesingh S, Georgiou M, Prasannan N, Sriskandarajah P.   +3 more
europepmc   +1 more source

Comparación de la eficacia de filgotinib, tofacitinib, baricitinib y upadacitinib en artritis reumatoide

Resumen Objetivo: Establecer, mediante una comparación indirecta (CI), si filgotinib, tofacitinib, baricitinib y upadacitinib pueden considerarse alternativas equivalentes en eficacia para el tratamiento de la artritis reumatoide.
Sánchez Casanueva,T, Merino Almazán,M, Claramunt García,R   +2 more
core  

Effect of JAK Inhibitors on Fatigue and Sleep Quality in Patients with Rheumatoid Arthritis: A Narrative Review. [PDF]

J Clin Med
Kowalska A, Borkowska A, Jawoszek A, Chmielewski G, Jaśkiewicz Ł, Krajewska-Włodarczyk M.   +5 more
europepmc   +1 more source

Clinical and Pharmacogenetic Factors Associated with Response to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Real-World Study of <i>JAK1</i>, <i>JAK2</i>, and <i>JAK3</i> Gene Variants. [PDF]

Pharmaceutics
Roldán AM, Márquez Pete N, Sánchez Suárez MDM, Rojo Tolosa S, Jiménez Morales A.   +4 more
europepmc   +1 more source

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study. [PDF]

Clin Rheumatol
Abdellaoui S, Al Tabaa O, Hilliquin S, d'Alessandro R, Hecquet S, Thomas M, Carvès S, Combier A, Allanore Y, Avouac J.   +9 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. [PDF]

Adv Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD).   +62 more
europepmc   +1 more source